Mustang Bio (MBIO) Releases Earnings Results, Beats Expectations By $0.03 EPS

Mustang Bio (NASDAQ:MBIO) issued its earnings results on Friday. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03, MarketWatch Earnings reports.

Shares of MBIO stock traded up $0.24 on Friday, reaching $4.32. The stock had a trading volume of 1,440,028 shares, compared to its average volume of 3,028,378. The stock has a market cap of $122.34 million, a price-to-earnings ratio of -3.79 and a beta of 2.57. Mustang Bio has a 12 month low of $2.18 and a 12 month high of $10.20.

An institutional investor recently raised its position in Mustang Bio stock. Geode Capital Management LLC increased its position in Mustang Bio Inc (NASDAQ:MBIO) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 170,217 shares of the company’s stock after purchasing an additional 6,741 shares during the quarter. Geode Capital Management LLC owned approximately 0.62% of Mustang Bio worth $500,000 as of its most recent SEC filing. Institutional investors own 8.60% of the company’s stock.

A number of brokerages have recently issued reports on MBIO. ValuEngine cut shares of Mustang Bio from a “buy” rating to a “hold” rating in a report on Wednesday, May 1st. Zacks Investment Research cut shares of Mustang Bio from a “hold” rating to a “sell” rating in a report on Friday, March 22nd. Finally, Oppenheimer set a $18.00 target price on shares of Mustang Bio and gave the company a “buy” rating in a report on Tuesday, March 19th.

ILLEGAL ACTIVITY WARNING: “Mustang Bio (MBIO) Releases Earnings Results, Beats Expectations By $0.03 EPS” was originally posted by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at

Mustang Bio Company Profile

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Further Reading: How to interpret Moving Average Convergence Divergence (MACD)

Earnings History for Mustang Bio (NASDAQ:MBIO)

Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with's FREE daily email newsletter.